Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plenum Osshp + injectable platelet-rich fibrin is a combination therapy used primarily in regenerative and oral-maxillofacial medicine, notably in bone grafting and sinus elevation procedures[1]. Plenum Osshp is a synthetic or xenogenic bone substitute (details on composition not available in search results) employed as a scaffold to support bone regeneration. Injectable platelet-rich fibrin (i-PRF) is an autologous blood-derived biomaterial made from the patient's own blood, spun to yield a concentrated fraction rich in platelets, leukocytes, cytokines, and growth factors embedded within a fibrin matrix[3][6]. This combination enhances healing by both providing a scaffold (Plenum Osshp) and delivering a sustained release of growth factors and pro-regenerative cytokines (i-PRF)[1][6]. The i-PRF component acts by stimulating angiogenesis, tissue regeneration, reducing inflammation, and supporting stem cell recruitment and differentiation[3][5][6]. This combination is being investigated for accelerating bone and soft tissue regeneration and reducing healing times in surgeries such as maxillary sinus augmentation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plenum Osshp + injectable platelet-rich fibrin.